Skip to main content

Cardinal Health Value Stock - Dividend - Research Selection

Cardinal health

ISIN: US14149Y1082 , WKN: 880206

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cardinal Health, Inc. operates as an integrated healthcare services and products company worldwide. The company\'s Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare, and consumer products to retailers, hospitals, and other healthcare providers. It offers distribution, inventory management, data reporting, new product launch support, and chargeback administration services to pharmaceutical manufacturers; pharmacy and medication therapy management, and patient outcomes services to hospitals, other healthcare providers, and payers; and consulting, patient support, and other services to pharmaceutical manufacturers and healthcare providers. This segment also operates nuclear pharmacies and manufacturing facilities that manufacture, prepare, and deliver radiopharmaceuticals, as well as operates direct-to-patient specialty pharmacies; offers logistics, marketing, and other services; and repackages generic pharmaceuticals and over-the-counter healthcare products. The company\'s Medical segment manufactures and sources medical, surgical, and laboratory products, including cardiovascular and endovascular products; wound care products; surgical drapes, gowns, and apparel; exam and surgical gloves; fluid suction and collection systems; and incontinence, enteral feeding, urology, operating room supply, electrode and needle, and syringe and sharps disposal product lines. It also distributes medical, surgical, and laboratory products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers, as well as to patients in the home; and assembles and sells sterile and non-sterile procedure kits. In addition, it offers supply chain services to healthcare providers; and post-acute care management, and transition services and software to hospitals, other healthcare providers, and payers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"

2025-09-03
Cardinal (CAH) could produce exceptional returns because of its solid growth attributes.

Should Value Investors Buy Cardinal Health (CAH) Stock?

2025-09-03
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

2 Reasons to Watch CAH and 1 to Stay Cautious

2025-09-03
Since September 2020, the S&P 500 has delivered a total return of 85.4%. But one standout stock has more than doubled the market - over the past five years, Cardinal Health has surged 198% to $149.15 per share. Its momentum hasn’t stopped as it’s also gained 15.5% in the last six months, beating the S&P by 5.8%.

Cardinal Health's (NYSE:CAH) investors will be pleased with their stellar 242% return over the last five years

2025-08-31
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term

2025-08-29
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Cirtec Medical Announces Appointment of New Chief Executive Officer

2025-08-28
BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical, a leading strategic outsourcing partner for complex minimally invasive, active implantable devices and precision components, is pleased to announce the appointment of Shar Matin as Chief Executive Officer, effective September 2, 2025. Shar brings more than 25 years of global leadership experience in the medical technology sector, with a proven track record of scaling businesses, driving innovation, and building strong custom

Should You Add Zimmer Biomet Stock to Your Portfolio Now?

2025-08-28
ZBH rides on knee innovation and robotics growth, but debt and macro pressures challenge its upside potential.

Cardinal Health Inc. stock outperforms competitors on strong trading day

2025-08-27
Cardinal Health Inc. stock outperforms competitors on strong trading day

Best Dividend Aristocrats For September 2025

2025-08-27
Discover top Dividend Aristocrats for 2025! Explore undervalued picks with 10%+ annualized returns, robust payout growth, and reliable income opportunities.

3 Dividend Aristocrats on Sale: Oversold, High Quality, and Built to Last

2025-08-27
Three oversold Dividend Aristocrats rated ‘Buy’ by Wall Street—rare bargains offering income, stability, and rebound potential.